In line Q4 sales; lower-than-expected 2024 guidance
08/02/24 -"Ipsen’s Q4 sales met expectations. Healthy growth in Oncology and a positive contribution from Rare Disease portfolio were somewhat offset by the decline in Neuroscience. Meanwhile, markets were ..."
Pages
51
Language
English
Published on
08/02/24
You may also be interested by these reports :
25/08/25
Attractive return potential remains – Confidence slightly raised
22/08/25
Though missing expectations, Novonesis demonstrated strong momentum in H1 2025, achieving 9% organic growth and 8% in Q2, resulting in a narrowed ...
21/08/25
Guidance reaffirmed while FX and destocking mask momentum
20/08/25
Following Donald Trump’s tariff threats and given the generic/biosimilar medicine makers’ relatively thin profitability, the markets were quick to ...